MarginsXMarginsX
Home › Markets › Health Care › BNTX

BioNTech SE American Depositary Share (BNTX)

BNTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$85.26
-0.40% on the day
Market cap
$21.4B
Large cap
Revenue · 2025
$3.2B
+4.3% on 2024
Net income · 2025
-$1.3B
-39.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/0001776985-26-000017-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerBNTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryGermany
IPO year2019
SEC CIK0001776985
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inGermany

Financials · 2025

LineValue
Revenue$3.2B
Net income-$1.3B
Operating income-$1.6B
Net margin-39.6%
Operating margin-49.0%
Revenue growth+4.3%
Cash$8.5B
Total assets$24.3B
P/E (computed)Net income was not positive
P/S (computed)6.8×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
7.7B EUR cash at December 31, 2025
Share count, 1 year
+5.4%
2025-03-03 to 2026-03-31 · +4.9% over 3 years
Going-concern doubt
No
20-F filed March 10, 2026
Insider net buying, 12 months
-$69.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-10
Cash and burn7.7B EUR cash; operating cash flow 114.0M EUR a quarter.Report 2025-12-31
Shares outstanding252,884,261 (2026-03-31); 239,970,804 a year earlier; 240,993,998 three years earlier. the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures.Cover page 2026-03-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEY GmbH & Co. KG Wirtschaftspruefungsgesellschaft, Cologne, GermanyPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $69.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
2.9B EUR-1.1B EUR456.0M EUR7.7B EURNo debt tags2.9B EUR20-F 2026-03-10
FY 2024
2024-12-31
2.8B EUR-665.3M EUR207.7M EUR9.8B EURNo debt tags2.8B EUR20-F 2026-03-10
FY 2023
2023-12-31
3.8B EUR930.3M EUR5.4B EUR11.7B EURNo debt tags3.8B EUR20-F 2026-03-10
FY 2022
2022-12-31
17.3B EUR9.4B EUR13.6B EUR13.9B EURNo debt tags17.3B EUR20-F 2025-03-10
FY 2021
2021-12-31
19.0B EUR10.3B EUR889.7M EUR1.7B EUR301.5M EUR19.0B EUR20-F 2024-03-20
FY 2020
2020-12-31
482.3M EUR15.2M EUR-13.5M EUR1.2B EUR240.1M EUR482.3M EUR20-F 2023-03-27
FY 2019
2019-12-31
108.6M EUR-179.1M EUR-198.5M EUR519.1M EUR74.2M EUR108.6M EUR20-F/A 2022-10-26
FY 2018
2018-12-31
127.6M EUR-48.0M EUR-58.9M EUR411.5M EURNo debt tags127.6M EUR20-F 2021-03-30

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-11-14
Latest annual report20-F2026-03-10
Latest quarterly / interim6-K2026-11-10

Source: SEC EDGAR submissions feed, 590 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.2%
1 month-3.8%
3 months-7.1%
Year to date-10.1%
1 year-17.6%
From 52-week high-28.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
BIIBBiogen Inc.$251.65-0.69%$37.2B
TECHBio-Techne Corp$72.79-0.01%$11.4B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
RGENRepligen Corporation$162.78-2.99%$10.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier